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Abstract
Background: It was hypothesised that colorectal cancer (CRC) could be diagnosed in biopsies by
measuring the combined expression of a small set of well known genes. Genes were chosen based
on their role in either the breakdown of the extracellular matrix or with changes in cellular
metabolism both of which are associated with CRC progression
Findings:  Gene expression data derived from quantitative real-time PCR for the solute
transporter carriers (SLCs) and the invasion-mediating matrix metalloproteinases (MMPs) were
examined using a Linear Descriminant Analysis (LDA). The combination of MMP-7 and SLC5A8 was
found to be the most predictive of CRC.
Conclusion: A combinatorial analysis technique is an effective method for both furthering our
understanding on the molecular basis of some aspects of CRC, as well as for leveraging well defined
cancer-related gene sets to identify cancer. In this instance, the combination of MMP-7 and SLC5A8
were optimal for identifying CRC.
Findings
Colorectal cancer is the third-most common cancer in
males and second-most common in females worldwide
[1]. Its prevalence highlights a need to more deeply under-
stand the molecular interactions that lead to its progres-
sion. Two important and well documented pathways in
the progression of colorectal cancer are changes in energy
source for cellular metabolism and break down of the
extracellular matrix.
Healthy colonocytes use short-chain monocarboxylates,
in particular butyrate, as their main source of energy [2].
The solute-linked carrier (SLC) SLC5A8, a Na+-coupled
transporter, and monocarboxylate transporter (MCT1)
SLC16A, are possibly vehicles by which short-chain
monocarboxylates are transported into the colonic epithe-
lium [3-5]. SLC5A8 and SLC16A1 have been purported to
provide a mechanism for the suppression of tumour
growth in colorectal and gastric cancers [3,6] and are
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down-regulated with tumour progression [4]. As colono-
cytes become cancerous there is a shift in energy source
away from butyrate to glucose, resulting in increased lev-
els of glucose in colorectal cancer cells [7] and in carcino-
mas [8]. Associated with this is an up-regulation of the
glucose transporter SLC2A1, which has been shown in a
significant proportion of aggressive human tumours [e.g.
[9]]. Together, these changes are believed to facilitate
tumour growth and proliferation [10].
Matrix metalloproteinases (MMPs) are a family of zinc-
and calcium-dependent proteolytic enzymes that degrade
macromolecules of the extracellular matrix. Members of
this family, such as MMP-2, -9 and -7, have been shown
to be associated with the breakdown of type IV collagen
and the basement membrane. They have been implicated
in tumour progression and invasion in human cancer tis-
sues [11-13]. The proteolytic activity of some MMPs (e.g.
MMP-2, -9 and -14) can be suppressed by Reversion-
inducing cysteine-rich protein with kazal motifs (RECK)
[14]. Decreased expression of RECK is believed to result in
increased invasion, metastasis and angiogenesis [reviewed
by [15]] and is associated with poor prognosis in cancer
patients [16].
This paper investigates genes in combination from two
previous well defined processes in colorectal cancer. The
abundance of transcripts from well described candidate
genes implicated in either the tumorigenic process or met-
abolic changes associated with carcinogenesis were exam-
ined in human colorectal cancer cell lines and human
cancer and healthy colonic tissues. In particular, the
expression of the nutrient transporter genes (SLC2A1,
SLC16A1 and SLC5A8), genes encoding proteins involved
in tissue remodelling and tumour invasion (MMP-2, -7, -
9 and -12, and the MMP regulator RECK), were examined
in two sets of normal human colon and colorectal tumour
samples and in four human colorectal cancer cell lines.
The study used a combinatorial transcript expression bio-
informatic approach to leverage described information on
a small gene set in order to discriminate between normal
and colorectal tumour tissue and help to define interrela-




Human colon tissue was sourced from the Division of Tis-
sue Pathology, Institute of Medical and Veterinary Sci-
ence, University of Adelaide. There were two sets of
normal and CRC tissues as outlined in Table 1 (for further
details of these samples [see Additional file 1 Tables S1
and S2].
Total RNA extraction, cDNA synthesis and real-time PCR
The human tissue samples were obtained from resections
of specimens and placed in OCT (optimal cutting temper-
ature cryopreservation medium) [17], snap-frozen in liq-
uid nitrogen and then stored at -86°C. After histological
verification RNA was extracted by placing samples in 1 ml
of Trizol® Reagent (Invitrogen, Sydney, Australia), then
homogenised using beads (mix of 2.5 mm glass and 0.1 –
1.0 mm diameter silicon-zirconium beads) in a MiniBead-
beater-8™ (BioSpec Products Inc., Oklahoma, USA) and
extracted according to Invitrogen's instructions. Samples
were then further processed using RNAeasy mini spin col-
umns (QIAGEN, Doncaster, Australia) with contaminat-
ing DNA being removed via DNase on-column digestion
as per the manufacturer's instructions. Similarly, cultured
cells that were at least 70% confluent were extracted
directly using the RNAeasy spin columns. The integrity of
RNA samples from Study 2 and the cell lines were checked
using a Bioanalyzer 2100 (Agilent Technologies) [18]. All
of the RNA samples were then quantified using a Nano-
Drop® ND-1000 Spectrophotometer. Samples were then
diluted to100 ng/ul.
cDNA was synthesised using SuperScript II (Invitrogen)
reverse transcriptase (Invitrogen) using 1 ug of RNA per
20 uL reaction and incubated as outlined in the manufac-
turer's instructions. Real-time PCR assays were conducted
using off-the shelf optimised and guaranteed TaqMan®
Gene Expression Assays (Applied Biosystems, Foster City,
California, USA), that consisted of primers and a probe
for the specific genes (Table 2). Three housekeeping genes
were used: the conventional reference gene 18S ribosomal
RNA (18S) [e.g. [19]], as well as a ribosomal protein (large
P0, a component of the 60S subunit) and HUWE1 (see
Table 2). The latter two were identified as suitable using a
Table 1: Summary of tissue sample details^
Site Normal Tumour pathology
Dukes A Dukes B Dukes C Dukes D
Study 1 Left 4 2 1 2 -
Right 1 2 - 2 -
Study 2 Left 6 1 4 2 -
Right 6 1 4 - 1
Transverse 2 - - 1 -
^see Additional file 1 for more details.BMC Research Notes 2009, 2:164 http://www.biomedcentral.com/1756-0500/2/164
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commercial database from Gene Logic (Gaithersburg,
Maryland, U.S.A.). The database contains information on
44928 probe-sets (HUG-133A and B Affymetrix arrays)
derived from 462 individuals covering the classes: normal
222; adenoma 29; cancer 161; and other disease 50. The
dataset was normalized using the GCRMA algorithm [20]
and then probe-sets were selected that had minimal vari-
ance across all arrays and had appreciable expression lev-
els. The aim was to use three housekeeping genes of
varying abundance (18s as the highest and HUWEI as the
lowest) to cover the range of target transcript differential
expression. Also, the target and housekeeping gene assays
were selected where possible to prime over an intron-exon
boundary to avoid amplifying any contaminating
genomic DNA (which could otherwise bias results). The
assays were then set up in four aliquots per cDNA sample
using TaqMan® Universal PCR Master Mix commensurate
with the manufacture's instructions, except that 5 μl reac-
tion volumes were used. Assays consisted of 20× mix of
unlabeled PCR primers and TaqMan® MGB probe (FAM
dye-labelled). Assays were run in 384-well plates on an
Applied Biosystems PRISM® 7900HT real-time thermocy-
cler and analysed using Sequence Detection System soft-
ware (version 2.3) as outlined in the TaqMan®  Gene
Expression Assays protocol.
Data acquisition
Data on the expression levels of target and reference genes
were obtained in the form of crossing points [21] or
threshold (Ct) values. The target genes were then analysed
following the delta-delta Ct value procedure [22,23] with
the assumption that efficiency was 100% and amplicons
doubled each cycle. Briefly, the Ct for each housekeeping
gene (HK) was subtracted from each corresponding target
gene such that,
The mean of the normal tissues was used to create a refer-
ence tissue value. So,
and then,
This process allowed for the data to be analysed for arte-
facts, real-time PCR repeatability and stability of HK
expression. As three HK genes were used, the process was
then repeated with each housekeeping gene and the
median calculated; the ratio of the gene expression is 2-
ΔΔCt.
The normalised ΔΔCt data sets were then combined and
all subset variable selection with Linear Discriminant
Analysis (LDA) was performed to ascertain the best com-
bination of transcripts that separated tumour from nor-
mal. The error rate for the model was estimated using
'leave-one-out estimates' for cross validation [24].
Transcript expression from cultured colorectal cancer cell
lines (HT29, HCT116, Caco2 and LIM1215) was then
used to further test the optimal combinations using LDA.
ΔCt Ct Ct normalised target gene target gene HK gene =− ,
ΔCt n Ct Ct reference target gene  normal tissue HK gene, =− 1/ [ ] () a all normal tissues ∑
ΔΔ Δ Δ Ct Ct Ct normalised target gene reference =− .
Table 2: Gene and assay details.
Gene Name and Symbol Genbank accession numbers TaqMan Primer/Probe ID Product size
(bp)
Eukaryotic 18S rRNA. X_03205.1 Hs99999901_s1 187





Ribosomal protein, large, P0 (60s). NM_053275.3
NM_0011002.3
Hs99999902_m1 105
Matrix metalloproteinase 12 (MMP12). NM_002426 Hs00159178_m1 62
Matrix metalloproteinase 2 (MMP2) (gelatinase A, 72 kDa 
gelatinase, 72 kDa type IV collagenase).
NM_004530 Hs00234422_m1 83
Matrix metalloproteinase 7 (MMP7). NM_002423 Hs00159163_m1 101
Metalloproteinase 9 (MMP9)(gelatinase B, 92 kDa gelatinase, 92 
kDa type IV collagenase).
NM_004994 Hs00234579_m1 54
Reversion-inducing-cysteine-rich protein with kazal motifs 
(RECK).
NM_021111 Hs00221638_m1 76
Solute carrier family 2 (facilitated glucose transporter) member 
1: SLC2A1, alias Glut1.
NM_006516 Hs00197884_m1 70
Solute carrier family 5 (iodide transporter), member 8. NM_145913 Hs00377618_m1 88
Solute carrier family 16, member 1 (monocarboxylic acid 
transporter 1).
NM_003051 Hs00161826_m1 110BMC Research Notes 2009, 2:164 http://www.biomedcentral.com/1756-0500/2/164
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The effect of tissue sampling site (i.e. left, transverse or
right colon), the type of 'normal' and Dukes stage was also
analysed.
Results
The normalised data sets for all seven target genes for
study 1, which consisted of randomly grouped tumour
and normal, were analysed using LDA [see Additional file
1 for figure S1, Additional file 2 for the raw Ct values],
resulting in a separation of the normal and tumour sam-
ples (the leave-one-out error estimate from the LDA is
0.25, [see Additional file 1 – Figure S2]. Using an all sub-
sets variable selection procedure with LDA created a
reduced model using only RECK and MMP-7 (see Figure
1), giving an improved leave-one-out error estimate of
0.06. Note, all the 'normal' samples clustered together
regardless of their source (i.e. from a CRC or healthy
patient). Therefore, there was no effect by the source of
'normal'.
For study 2, which consisted of paired data, the normal-
ised data sets for all seven target genes were then analysed
using LDA [see Additional file 1 – Figure S3 and Addi-
tional file 3 for raw Ct values], resulting in separation of
the normal and tumour samples (the leave-one-out error
estimate from the LDA is 0.178, [see Additional file 1 fig-
ure S4]. This separation was further increased using an all
subsets variable selection procedure with LDA. The result-
ant reduced model, this time using only MMP7 and
SLC5A8, had a leave-one-out error estimate from the LDA
of 0.035 (see Figure 2).
When data from both the human tissue studies were com-
bined and LDA applied to the four classes (Study 1 nor-
mal, Study 1 tumour, Study 2 normal, Study 2 tumour);
the two sets of 'normals' could not be separated and the
two sets of 'tumours' could not be separated. This indi-
cates that it is feasible to combine the studies. The optimal
transcript combination that separated tumour from nor-
mal was SLC5A8 and MMP-7 (see Figure 3) resulting in a
leave-one-out error estimate of 0.128. There was no effect
of sampling site (i.e., left, right or transverse colon) or
Duke's stage on the expression of MMP-7 or SLC5A8.
Then, as an exercise to test the mathematics of this
approach, the two studies plus CRC cell line data [see
Additional file 1 for Figure S5 and Additional file 3 for raw
Ct values] were then combined. The maximum separation
between tissue types (normals, as opposed to tumour tis-
sue plus cell lines) occurred with the transcript combina-
tion of MMP-7, RECK and SLC5A8 (see Figure 4).
Discussion
This communication investigated expression patterns of
transcripts associated with processes involved in the
development of colorectal cancer. Genes examined were
the solute transporters SLC2A1, SLC5A8 and SLC16A1,
which are associated with changes in the cellular import
Box plot of the optimal transcript model for separating nor- mal (healthy) and tumour colon tissue from Study 1 Figure 1
Box plot of the optimal transcript model for separat-
ing normal (healthy) and tumour colon tissue from 
Study 1. LDA scores resulted from the combined normal-
ised gene data set reduced down to an optimal model of 
RECK and MMP-7.
Box plot of the optimal transcript model for separating nor- mal (healthy) and tumour colon tissue from Study 2 Figure 2
Box plot of the optimal transcript model for separat-
ing normal (healthy) and tumour colon tissue from 
Study 2. LDA scores resulted from the combined normal-
ised gene data reduced down to an optimal model of MMP7 
and SLC5A8.
normal             tumourBMC Research Notes 2009, 2:164 http://www.biomedcentral.com/1756-0500/2/164
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of energy sources, and MMP-2, MMP-7, MMP-9 and
MMP-12, which are related to the breakdown of the extra-
cellular matrix, and the MMP negative regulator, RECK.
Individual differential gene expression patterns were
established for normal and cancerous tissue samples.
When the data were combined, a combination of MMP-7
and SLC5A8 (and, to a lesser extent, RECK) provided the
greatest separation between healthy colon tissue and
colorectal cancer (tissue or cell lines). One possible inter-
pretation of these results is that the mechanisms which act
to break down the extracellular matrix and promote
tumour invasion also induce MMP negative regulation.
Whilst in parallel, SLC5A8 levels in tumours were reduced
compared to normal tissue and cell lines, which is consist-
ent with previous studies [4] showing an association
between SLC5A8 down-regulation and tumour progres-
sion.
This study has demonstrated that it is advantageous to use
a combinatorial approach to defining biomarkers of car-
cinogenesis processes compared to using individual can-
didate transcript markers. Others have used systematic
approaches when analysing transcripts for cancer biomar-
kers (e.g. pancreatic cancer by [25]) and have shown that
markers, which individually are suboptimal, can be com-
bined to yield higher sensitivity and specificity. Even
though our study uses a small patient tissue library, it
demonstrates a proof-of-concept for the combinatorial
approach to transcript biomarkers that now needs to be
validated in larger controlled data sets [26,27]. In addi-
tion, our technique may prove useful to validate other
colorectal cancer candidate transcripts, such as those
defined in a recent study [28] which applied a meta-anal-
ysis or genome wide studies (e.g. microarrays) to compre-
hensively evaluate microarray data for biomarkers.
Although using tumour-related gene expression may not
be an optimal platform for colorectal cancer detection,
this combinatorial approach demonstrates a method for
biomarker discovery based on a priori hypotheses origi-
nating from other studies that may prove useful either in
elucidating early biomarkers or in establishing auxiliary
markers of prognosis. This approach could be applied in
the clinical setting to increase the sensitivity and specifi-
city of biomarkers by combining the analyses with other
markers [29].
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